DE69737793D1 - Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs - Google Patents

Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs

Info

Publication number
DE69737793D1
DE69737793D1 DE69737793T DE69737793T DE69737793D1 DE 69737793 D1 DE69737793 D1 DE 69737793D1 DE 69737793 T DE69737793 T DE 69737793T DE 69737793 T DE69737793 T DE 69737793T DE 69737793 D1 DE69737793 D1 DE 69737793D1
Authority
DE
Germany
Prior art keywords
benzimidazole
carbamate
cancer
treatment
viral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69737793T
Other languages
English (en)
Inventor
James Berger Camden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UAF Technologies and Research LLC
Original Assignee
UAF Technologies and Research LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UAF Technologies and Research LLC filed Critical UAF Technologies and Research LLC
Application granted granted Critical
Publication of DE69737793D1 publication Critical patent/DE69737793D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69737793T 1997-05-16 1997-11-26 Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs Expired - Lifetime DE69737793D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/857,811 US6506783B1 (en) 1997-05-16 1997-05-16 Cancer treatments and pharmaceutical compositions therefor
PCT/US1997/021565 WO1998051304A1 (en) 1997-05-16 1997-11-26 Benzimidazole-2-carbamates for the treatment of viral infections and cancer

Publications (1)

Publication Number Publication Date
DE69737793D1 true DE69737793D1 (de) 2007-07-19

Family

ID=25326784

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69737793T Expired - Lifetime DE69737793D1 (de) 1997-05-16 1997-11-26 Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs

Country Status (22)

Country Link
US (13) US6506783B1 (de)
EP (1) EP0956017B1 (de)
JP (1) JP2001527523A (de)
KR (1) KR20000049065A (de)
CN (1) CN1254282A (de)
AR (1) AR010008A1 (de)
AT (1) ATE363904T1 (de)
AU (1) AU728690B2 (de)
BR (1) BR9714634A (de)
CA (1) CA2268840C (de)
CZ (1) CZ125299A3 (de)
DE (1) DE69737793D1 (de)
HU (1) HUP0001170A3 (de)
IL (1) IL129352A0 (de)
NO (1) NO991700L (de)
NZ (1) NZ335159A (de)
PE (1) PE11099A1 (de)
PL (1) PL335541A1 (de)
SK (1) SK47099A3 (de)
TR (1) TR199901528T2 (de)
WO (1) WO1998051304A1 (de)
ZA (1) ZA979096B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
US6177460B1 (en) 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
US6245789B1 (en) 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6423734B1 (en) * 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6608096B1 (en) 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6407105B1 (en) * 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles
CA2430897C (en) * 2000-12-07 2010-11-16 Universiteit Utrecht Holding B.V. Liposomal composition comprising water-soluble corticosteroids for the treatment of inflammatory disorders
AU2002248341B8 (en) * 2001-01-11 2007-03-29 Board Of Regents, The University Of Texas System Antihelminthic drugs as a treatment for hyperproliferative diseases
US6515074B2 (en) * 2001-01-22 2003-02-04 Delphi Technologies, Inc. Thermoplastic polymer alloy compositions and process for manufacture thereof
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders
AUPR626001A0 (en) * 2001-07-10 2001-08-02 Mcgregor, Neil A method of treatment and/or prophylaxis
JP2005508322A (ja) * 2001-09-24 2005-03-31 ジェシー エル エス オウ 併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
JP2005521712A (ja) * 2002-03-26 2005-07-21 アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナ 弱塩基の可溶化
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
US8492443B2 (en) * 2002-07-08 2013-07-23 Joe S. Wilkins, Jr. Treatment for herpes simplex virus and other infectious diseases
EP1393720A1 (de) * 2002-08-27 2004-03-03 Universiteit Utrecht Vesikel enthaltend Corticosteroide zur Behandlung von Krebs
AU2003900064A0 (en) * 2003-01-09 2003-01-23 Penam Investments Pty. Ltd. A method of treatment or prophylaxis of viral infection.
EP1608628A2 (de) 2003-03-17 2005-12-28 Takeda San Diego, Inc. Inhibitoren der histondeacetylase
EP1598353A1 (de) * 2004-05-17 2005-11-23 Boehringer Ingelheim International GmbH Pyrrolobenzimidazolone und ihre Verwendung als als antiproliferative Mittel
US8138342B2 (en) * 2004-10-12 2012-03-20 High Point Pharmacueticals, LLC 11β-hydroxysteroid dehydrogenase type 1 active spiro compounds
US7193254B2 (en) * 2004-11-30 2007-03-20 International Business Machines Corporation Structure and method of applying stresses to PFET and NFET transistor channels for improved performance
EP1830847B1 (de) * 2004-12-06 2014-11-19 Pitney Pharmaceuticals Pty Limited Krebsbehandlung
AU2006209951B2 (en) 2005-02-04 2011-04-14 Survac Aps Survivin peptide vaccine
US7265248B1 (en) 2005-04-29 2007-09-04 Technology Innovations, Llc Compositions and methods for the treatment of malaria
EP1948190A2 (de) * 2005-11-01 2008-07-30 Transtech Pharma Pharmazeutische verwendung von substituierten amiden
KR20080069189A (ko) * 2005-11-01 2008-07-25 트랜스테크 파르마, 인크. 치환된 아미드의 약학적 사용
CA2883060C (en) * 2005-11-09 2019-01-08 Philera New Zealand Limited Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits
CA2642813A1 (en) * 2006-02-28 2007-09-07 Merck & Co., Inc. Inhibitors of histone deacetylase
US20100168083A1 (en) * 2006-03-21 2010-07-01 Soren Ebdrup Adamantane derivatives for the treatment of the metabolic syndrome
AU2007236049A1 (en) 2006-04-07 2007-10-18 High Point Pharmaceuticals, Llc 11beta-hydroxysteroid dehydrogenase type 1 active compounds
EP2029726A4 (de) * 2006-06-09 2010-07-28 Univ Miami Beurteilung der zellenzusammensetzung und fraktionelle durchführbarkeit und verwendungen davon
EP2038255A2 (de) * 2006-06-16 2009-03-25 High Point Pharmaceuticals, LLC Pharmazeutische verwendung substituierter piperidincarbonsäureamide
US8048908B2 (en) * 2006-07-13 2011-11-01 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
EP1878721A1 (de) * 2006-07-13 2008-01-16 Novo Nordisk A/S 4-Piperidylbenzamide als Inhibitoren der 11-beta-hydroxysteroiddehydrogenase Typ 1
US20110003852A1 (en) * 2007-02-23 2011-01-06 Soren Ebdrup N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EA016951B1 (ru) 2007-02-23 2012-08-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи N-АДАМАНТИЛБЕНЗАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ 11-β-ГИДРОКСИСТЕРОИДДЕГИДРОГЕНАЗЫ
WO2008101907A2 (en) * 2007-02-23 2008-08-28 High Point Pharmaceuticals, Llc N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase
EP2125704A1 (de) * 2007-02-23 2009-12-02 High Point Pharmaceuticals, LLC N-adamantylbenzamide als inhibitoren von 11-beta-hydroxysteroiddehydrogenase
JP2010520864A (ja) * 2007-03-09 2010-06-17 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー ヒドロキシステロイドデヒドロゲナーゼインヒビターとしてのインドール−及びベンズイミダゾールアミド類
US20100056600A1 (en) * 2007-03-28 2010-03-04 Soren Ebdrup 11beta-hsd1 active compounds
CN101677562A (zh) * 2007-04-11 2010-03-24 高点制药有限责任公司 新化合物
JP2010526777A (ja) * 2007-04-24 2010-08-05 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 置換アミドの医薬用途
AU2008269154B2 (en) * 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
JP2010531358A (ja) * 2007-06-27 2010-09-24 メルク・シャープ・エンド・ドーム・コーポレイション ヒストン脱アセチル化酵素阻害剤としてのピリジル及びピリミジニル誘導体
WO2009148623A2 (en) * 2008-06-05 2009-12-10 Stc.Unm Methods and related compositions for the treatment of cancer
US8771693B2 (en) 2009-10-27 2014-07-08 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2012015715A1 (en) 2010-07-27 2012-02-02 High Point Pharmaceuticals, Llc Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta hsd1 modulators
US10487114B2 (en) 2011-04-27 2019-11-26 Beth Israel Deaconess Medical Center, Inc. Methods for administering peptides for the generation of effective c/s conformation-specific antibodies to a human subject in need thereof
WO2013170012A2 (en) 2012-05-09 2013-11-14 Western University Of Health Sciences Proliposomal testosterone formulations
WO2014082085A1 (en) * 2012-11-26 2014-05-30 The University Of North Carolina At Chapel Hill Use of itk inhibitors for the treatment of cancer
WO2016077648A1 (en) * 2014-11-11 2016-05-19 Neymeyer Calvin E Method of treating pre-cancerous lesion with glyphosate, and compositions thereof
WO2016187767A1 (en) * 2015-05-25 2016-12-01 Hutchison Medipharma Limited Pharmaceutical compositions and use thereof
WO2018081361A1 (en) * 2016-10-28 2018-05-03 Children's Hospital Medical Center Methods and compositions for treatment of myelodyspastic syndromes and/or acute myleoid leukemias
CN109633026A (zh) * 2019-01-03 2019-04-16 上海市农业科学院 一种液相色谱-串联质谱检测多菌灵及其代谢物的方法
EP3907230A1 (de) 2020-03-30 2021-11-10 Biometrix Technology Inc. Neue benzimidazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antikrebsmittel
KR102583547B1 (ko) 2020-03-30 2023-10-06 (주)바이오메트릭스 테크놀로지 신규한 벤지미다졸 유도체, 이의 제조방법 및 이의 항암제 용도
KR102449266B1 (ko) 2020-06-23 2022-09-30 (주)바이오메트릭스 테크놀로지 항암 활성 그리고 항바이러스 활성을 갖는 신규한 벤지미다졸-탄수화물 결합체 화합물(Benzimidazole carbohydrate conjugate compound) 및 이의 제조 방법
KR102342313B1 (ko) 2021-08-27 2021-12-24 (주)바이오메트릭스 테크놀로지 벤지미다졸-탄수화물 결합체 화합물을 포함하는 미셀, 이의 제조방법, 이의 항암제 또는 항바이러스제로서의 용도

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE136499C (de)
DE158398C (de)
US2933502A (en) 1958-02-12 1960-04-19 Du Pont Benzimidazolone derivatives
US3010968A (en) 1959-11-25 1961-11-28 Du Pont Process for manufacture of certain alkyl esters of benzimidazole carbamic acids
NL134354C (de) 1963-05-23
US3499761A (en) 1964-07-20 1970-03-10 Gaf Corp Silver halide emulsions containing alkyl esters of benzimidazole carbamic acid antifogging agents
BE666795A (de) 1964-08-04 1966-01-13
USRE28403E (en) 1964-08-04 1975-04-29 Butyl and n-propoxy-z-carbo- methoxyaminobenzimidazoles
US3541213A (en) 1966-05-06 1970-11-17 Du Pont Fungicidal and mite ovicidal substituted 2-aminobenzimidazoles
US3399212A (en) 1966-05-16 1968-08-27 Smith Kline French Lab Benzimidazole ureas
US3480642A (en) 1967-03-22 1969-11-25 Smithkline Corp Process for producing 2-carbalkoxyaminobenzimidazoles
US3881014A (en) 1968-11-05 1975-04-29 Bayer Ag N-tritylimidazoles for treating fungal infections
BE744970A (fr) 1969-01-28 1970-07-27 Lilly Co Eli Agents antiviraux et immuno-depresseurs
BE759337A (fr) 1969-11-24 1971-05-24 Lilly Co Eli Benzimidazol (2,1-b)-quinazolin (6h) ones qui sont des immuno-depresseurs, et nouvelles benzimidazo (2,1-b) quinazolin-12-(6h) ones
FR2046114A5 (en) 1970-01-30 1971-03-05 Dynachim Sarl Benzimidazole derivs anthelmintic, antifung - al bactericidal, aericidal, insecticidal, nema
US3956262A (en) 1970-12-09 1976-05-11 Beecham Group Limited Triazenoimidazoles
US3738995A (en) 1971-05-14 1973-06-12 Du Pont Solvent process for the preparation of 1 - carbamoyl-substituted 2 - benzimidazolecarbamates
DE2144505A1 (de) 1971-09-06 1973-03-15 Boehringer Sohn Ingelheim S-triazino- eckige klammer auf 1,2-a eckige klammer zu-benzimidazole
FR2155888A1 (en) 1971-10-13 1973-05-25 Agot Aime Solid anthelmintic composn - for more economical treatment of ruminants
DE2227919C2 (de) 1972-06-08 1982-12-23 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung von Benzimidazol-2-yl-carbaminsäure-methylester
DE2253324A1 (de) 1972-10-31 1974-05-09 Bayer Ag 1-alkoxycarbonyl-2- eckige klammer auf bis-(alkoxycarbonyl)-amino eckige klammer zu -benzimidazole, verfahren zu ihrer herstellung, sowie ihre verwendung als fungizide
US4046906A (en) 1973-04-21 1977-09-06 Hoechst Aktiengesellschaft Salts of alkyl 2-benzimidazole-carbamate
JPS5142565A (en) 1974-10-09 1976-04-10 Copal Co Ltd onnoff taimaa
US4001423A (en) 1975-06-20 1977-01-04 Dodds Dale I 2-(2-ethoxy)ethoxyethyl benzimidazolecarbamate
DE2527677A1 (de) 1975-06-21 1977-01-20 Bayer Ag Verfahren zur herstellung von 2,4- dioxo-1,2,3,4-tetrahydro-s-triazino- eckige klammer auf 1,2-a eckige klammer zu -benzimidazolen
US4086235A (en) 1976-04-12 1978-04-25 Syntex (U.S.A.) Inc. 5 (6)-Benzene ring substituted benzimidazole-2-carbamate derivatives having anthelmintic activity
IN159210B (de) 1982-01-11 1987-04-11 Council Scient Ind Res
IN158878B (de) 1982-07-15 1987-02-07 Council Scient Ind Res
HU193951B (en) 1985-03-11 1987-12-28 Richter Gedeon Vegyeszet Process for producing new sulfur-containing 5-substituted benzimidazol derivatives and pharmaceutical compositions containing them
US4731366A (en) 1986-08-05 1988-03-15 Harbor Branch Oceanographic Institution, Inc. Discorhabdin compositions and their methods of use
GB2210875B (en) 1987-10-09 1991-05-29 Farmos Oy Aromatase inhibiting 4(5)-imidazoles
US5329012A (en) 1987-10-29 1994-07-12 The Research Foundation Of State University Of New York Bis(acyloxmethyl)imidazole compounds
US5114951A (en) 1989-04-11 1992-05-19 Burroughs Wellcome Company Agents for combating multiple drug resistance
US5149527A (en) 1990-09-18 1992-09-22 Oncotech, Inc. Immunopotentiating protocol for chemotherapy-responsive tumors
US5284662A (en) 1990-10-01 1994-02-08 Ciba-Geigy Corp. Oral osmotic system for slightly soluble active agents
JPH04223274A (ja) 1990-12-26 1992-08-13 Kansei Corp 加速度センサ
GB9106278D0 (en) 1991-03-25 1991-05-08 Smithkline Beecham Plc Method of treatment
US5310748A (en) 1992-05-11 1994-05-10 The Du Pont Merck Pharmaceutical Company Imidazoles for the treatment of atherosclerosis
US5364875A (en) 1992-05-11 1994-11-15 The Du Pont Merck Pharmaceutical Company Imidazoles linked to bicyclic heterocyclic groups for the treatment of atherosclerosis
US5290801A (en) 1992-05-29 1994-03-01 The Du Pont Merck Pharmaceutical Company Benzimidazoles for the treatment of atherosclerosis
EP0655066A1 (de) 1992-08-12 1995-05-31 PHARMACIA & UPJOHN COMPANY Proteinkinase-inhibitoren und verwandte verbindungen kombiniert mit taxol
FR2703057B1 (fr) 1993-03-24 1995-06-16 Elysees Balzac Financiere Matériau alvéolaire cellulosique renfermant un agent biocide et procédé pour sa préparation.
CN1090186C (zh) 1993-03-31 2002-09-04 麦克公司 治疗aids药物组合物中的hiv蛋白酶抑制剂
US5434163A (en) 1993-05-14 1995-07-18 The Medical College Of Pennsylvania Treatment of Cryptococcus neoformans infection
US5554373A (en) 1993-11-05 1996-09-10 Seabrook; Samuel G. Compositions containing anti-microbial agents and methods for making and using same
JP3213471B2 (ja) 1994-04-13 2001-10-02 ポーラ化成工業株式会社 薬効成分含有リポソーム製剤の製造方法
ZA962879B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US6177460B1 (en) * 1995-04-12 2001-01-23 The Procter & Gamble Company Method of treatment for cancer or viral infections
AU714056B2 (en) 1995-04-12 1999-12-16 Uaf Technologies And Research Llc A pharmaceutical composition containing N-chlorophenylcarbamates and N-chlorophenylthiocarbamates for inhibiting the growth of viruses and cancers
US5665713A (en) 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6262093B1 (en) * 1995-04-12 2001-07-17 The Proctor & Gamble Company Methods of treating cancer with benzimidazoles
NZ305784A (en) 1995-04-12 2001-03-30 Procter & Gamble Benzimidazole containing medicaments for treating cancers, tumors and viral infections
US5629341A (en) 1995-04-12 1997-05-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
ZA962880B (en) 1995-04-12 1997-03-17 Procter & Gamble A pharmaceutical composition for inhibiting the growth of viruses and cancers
US5656615A (en) 1995-04-12 1997-08-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers and viruses in mammals
US6479526B1 (en) 1995-04-12 2002-11-12 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
US6200992B1 (en) * 1995-06-07 2001-03-13 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
MX9707809A (es) * 1995-06-07 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene bencimidazol para inhibir el crecimiento de canceres.
US5665751A (en) 1995-06-07 1997-09-09 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
US5770616A (en) 1995-06-07 1998-06-23 The Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of cancers
KR19990022617A (ko) 1995-06-07 1999-03-25 데이비드 엠 모이어 백혈병 치료용 약제의 제조를 위한 벤즈이미다졸의 용도
US20010039291A1 (en) 1995-06-07 2001-11-08 The Procter & Gamble Company Compositions and methods of treatment for cancer or viral infections
US6265427B1 (en) 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
PL324905A1 (en) 1995-08-03 1998-06-22 Procter & Gamble Application of griseofulvin in carcinoma development inhibition
US5908855A (en) 1996-07-16 1999-06-01 The Procter & Gamble Company Compositions for treating viral infections
US6686391B2 (en) 1995-08-04 2004-02-03 University Of Arizona Foundation N-chlorophenylcarbamate and N-chlorophenylthiocarbamate compositions
MX9707808A (es) 1995-08-04 1998-01-31 Procter & Gamble Una composicion farmaceutica que contiene n-clorofenilcarbamatos y n-clorofiniltiocarbamatos para inhibir el crecimiento de virus y canceres.
IL123095A0 (en) 1995-08-04 1998-09-24 Procter & Gamble Pharmaceutical compositions containing fluconazole for inhibiting the growth of cancers
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5627094A (en) * 1995-12-04 1997-05-06 Chartered Semiconductor Manufacturing Pte, Ltd. Stacked container capacitor using chemical mechanical polishing
US6541213B1 (en) * 1996-03-29 2003-04-01 University Of Washington Microscale diffusion immunoassay
DE19623226A1 (de) * 1996-06-11 1997-12-18 Basf Ag Katalysatorsysteme vom Typ der Ziegler-Natta-Katalysatoren
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5825811A (en) 1997-01-16 1998-10-20 Motorola, Inc. Method and apparatus for facilitating inbound channel access
US5900429A (en) 1997-01-28 1999-05-04 The Procter & Gamble Company Method for inhibiting the growth of cancers
US6506783B1 (en) * 1997-05-16 2003-01-14 The Procter & Gamble Company Cancer treatments and pharmaceutical compositions therefor
PE11499A1 (es) 1997-05-16 1999-03-01 Procter & Gamble Tratamiento del hiv y cancer
US5908885A (en) * 1997-07-01 1999-06-01 University Of South Alabama Polysuccinimide and polyaspartate as additives to cementitious materials
US6245789B1 (en) * 1998-05-19 2001-06-12 The Procter & Gamble Company HIV and viral treatment
US6248843B1 (en) * 1998-09-18 2001-06-19 Mcwhorter Technologies, Inc. Powder coatings based on branched oligoesters and triazole blocked polyisocyanates
EP1119345B1 (de) 1998-10-09 2009-04-29 General Mills, Inc. Verkapselung empfindlicher flüssiger komponenten in eine matrix zur gewinnung diskreter lagerbeständiger partikel
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US20010053773A1 (en) 1998-12-22 2001-12-20 The Procter & Gamble Company Method for inhibiting the growth of cancers
WO2000050015A1 (en) * 1999-02-23 2000-08-31 Yuhan Corporation Pharmaceutical capsule compositions containing loratadine and pseudoephedrine
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6423734B1 (en) 1999-08-13 2002-07-23 The Procter & Gamble Company Method of preventing cancer
US6135835A (en) * 1999-08-16 2000-10-24 Future Beach Corporation Aquatic vehicle
US6384049B1 (en) 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
US6290929B1 (en) 2000-07-28 2001-09-18 The Procter & Gamble Company Cancer treatment
US6518269B1 (en) 2000-07-28 2003-02-11 University Of Arizona Foundation Cancer treatment
US6380232B1 (en) 2000-09-26 2002-04-30 The Procter & Gamble Company Benzimidazole urea derivatives, and pharmaceutical compositions and unit dosages thereof
US6407105B1 (en) 2000-09-26 2002-06-18 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6462062B1 (en) 2000-09-26 2002-10-08 The Procter & Gamble Company Compounds and methods for use thereof in the treatment of cancer or viral infections
US6608096B1 (en) * 2000-09-26 2003-08-19 University Of Arizona Foundation Compounds and methods for use thereof in the treatment of cancer or viral infections
WO2002041891A2 (en) * 2000-11-01 2002-05-30 The Procter & Gamble Company Hiv treatment with benzimidazoles

Also Published As

Publication number Publication date
US6864275B1 (en) 2005-03-08
US6900235B1 (en) 2005-05-31
CN1254282A (zh) 2000-05-24
ZA979096B (en) 1998-08-28
JP2001527523A (ja) 2001-12-25
US6423736B1 (en) 2002-07-23
CA2268840C (en) 2006-10-03
AU7402798A (en) 1998-12-08
US6077862A (en) 2000-06-20
CZ125299A3 (cs) 1999-09-15
US6420411B1 (en) 2002-07-16
WO1998051304A1 (en) 1998-11-19
BR9714634A (pt) 2000-05-23
NO991700L (no) 2000-01-13
KR20000049065A (ko) 2000-07-25
SK47099A3 (en) 2000-05-16
US6984654B2 (en) 2006-01-10
IL129352A0 (en) 2000-02-17
NO991700D0 (no) 1999-04-09
EP0956017B1 (de) 2007-06-06
US6506783B1 (en) 2003-01-14
US6710065B1 (en) 2004-03-23
CA2268840A1 (en) 1998-11-19
US6407131B1 (en) 2002-06-18
TR199901528T2 (xx) 1999-09-21
EP0956017A1 (de) 1999-11-17
NZ335159A (en) 2001-09-28
US20050288349A1 (en) 2005-12-29
ATE363904T1 (de) 2007-06-15
AU728690B2 (en) 2001-01-18
PL335541A1 (en) 2000-04-25
AR010008A1 (es) 2000-05-17
HUP0001170A2 (hu) 2001-05-28
PE11099A1 (es) 1999-03-01
HUP0001170A3 (en) 2001-07-30
US6482843B1 (en) 2002-11-19
US20050119236A1 (en) 2005-06-02
US6423735B1 (en) 2002-07-23
US20050192328A1 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
ATE363904T1 (de) Benzimidazol-2-carbamat zur behandlung viraler infektionen und von krebs
DE69739758D1 (de) Vakzine zur behandlung von lymphomen und leukämie
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69812681D1 (de) Unsubstituierte polydiallylaminen zur behandlung von hypercholesterolemia
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69836752D1 (de) Prostaglandinagoniste und deren verwendung zur behandlung von knochenerkrankungen
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
DE69927971D1 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69830728D1 (de) Arzneimittel zur behandlung von häufigem wasserlassen und harninkontinenz
DE69806801D1 (de) Galenische präparation zur prävention und behandlung von hepatokarzinomen
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60030554D1 (de) Verwendungen von et743 zur behandlung von krebs
ATE414512T1 (de) Kombinationstherapie zur behandlung von krebs
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
DE69727240D1 (de) Kombinationen enthaltend vx478, zidovudin und 3tc zur behandlung von hiv
ATE347372T1 (de) Vakzine zur behandlung von mycosen
DE60027429D1 (de) Dihydrobenzodiazepinen und deren verwendung zur behandlung von dyslipidämien
DE69825319D1 (de) Präparat zur vorbeugung und behandlung von entzündungen
DE69823339D1 (de) Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen
ATE253578T1 (de) Oxazinochinolone zur behandlung von viralen infektionen
DE69834937D1 (de) Antibiotika zur behandlung von magengeschwuren
DE60001255D1 (de) Zusammensetzung zur Behandlung von Polyesterfaser
DE60021252D1 (de) Antikonvulsiva zur behandlung von autismus
DE69926485D1 (de) Behandlung von durchblasgasen
ATE346840T1 (de) Aminoalkylphenol-derivate zur behandlung von depression und gedächtnis-funktionsstörung

Legal Events

Date Code Title Description
8332 No legal effect for de